Sarepta seems confident that despite the missed primary endpoint, it can still achieve that objective. Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta ...

Roche entered into a worldwide partnership with Sarepta Therapeutics in 2019 to commercialise the gene therapy outside of the US. Subjects in the trial received one dose of Elevidys or a placebo ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Roche Holding AG (RHHVF – Research Report). Sarepta ...

As part of a collaboration agreement signed in 2019, Sarepta is working with Roche (RHHBY) to transform the future for the Duchenne community, enabling those living with the disease to maintain ...

Sarepta recorded around $37.4 million as collaboration and other revenues associated with commercial Elevidys supply to Roche. This metric also included $9.5 million received as royalty revenues ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

No new safety signals were observed. As part of a collaboration agreement signed in 2019, Sarepta is working with Roche Holdings AG RHHBY. Sarepta is responsible for regulatory approval and ...

Sarepta Therapeutics ... It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics ...

Nabaparna Bhattacharya Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained ...